Wegovy Pill Approved in the UK: A New Chapter in Weight Management
As someone who works in weight management every day, I find it fascinating to watch how quickly this field is evolving.
When I first began helping patients with their weight loss journeys, our options were relatively limited. Today, we have access to highly effective treatments that can genuinely change lives. Now, another significant development has arrived: the MHRA has approved a tablet form of Wegovy® (oral semaglutide) for weight management in the UK.
For many people, this may seem like a small change. After all, we already have Wegovy injections. However, from both a clinical and patient perspective, I believe this approval has the potential to make weight management treatment more accessible than ever before.
Our online service, Aster, has a waitlist to notify people when the tablets become available to provide as a treatment. You can follow the link below to join the list.
What Is the Wegovy Pill?
The new Wegovy pill contains semaglutide, the same active ingredient found in Wegovy injections.
Semaglutide belongs to a group of medicines known as GLP-1 receptor agonists. These medications work by mimicking hormones naturally produced in the body that help regulate appetite and satiety.
In simple terms, they help people feel fuller for longer, reduce food noise, decrease hunger and make it easier to maintain a calorie deficit without feeling as though they are constantly battling against their own biology.
Why Is This Approval Important?
One of the biggest misconceptions about weight management is that success simply comes down to willpower.
If that were true, we would not see so many intelligent, disciplined and motivated people repeatedly struggle with their weight despite genuinely trying.
Weight management is far more complex. Genetics, hormones, sleep, stress, medications, previous dieting history and environmental factors all influence how our bodies regulate hunger and energy balance.
The emergence of GLP-1 medicines has helped us better recognise obesity as a chronic health condition rather than a personal failing.
While many patients have embraced injectable treatments, others remain hesitant about needles. Some dislike self-injecting, some travel frequently and some simply prefer the familiarity of taking a tablet.
The approval of oral Wegovy may remove one of the final barriers preventing certain patients from seeking support.
How Effective Is Oral Semaglutide?
The results seen in clinical trials have been impressive.
Participants taking oral semaglutide achieved average weight losses of over 13% of their starting body weight during the study period, with even greater results seen among those who consistently adhered to treatment.
To put this into perspective, a person weighing 100 kg could potentially lose more than 13 kg during treatment when combined with appropriate lifestyle changes.
Of course, individual results vary significantly. Some people lose considerably more weight, while others achieve more modest results.
As with any treatment, medication is only one piece of the puzzle.
A Medication Is Not a Lifestyle
This is the most important point I discuss with patients.
No medicine teaches someone how to navigate emotional eating, automatically improves sleep habits, or rewrites years of learned behaviours around food.
What these medicines can do is create the physiological space required for meaningful change.
Many patients describe a reduction in constant hunger, cravings and food-related thoughts. This often allows them to finally focus on building sustainable habits rather than feeling trapped in a continuous cycle of restriction and relapse.
The goal should never be simply to lose weight, rather to create a healthier relationship with food, improve metabolic health and build habits that remain long after treatment has ended.
Who could be able to use oral Wegovy tablets?
The Wegovy pill has been licensed for adults living with obesity or overweight accompanied by weight-related health conditions.
Eligibility will generally mirror existing semaglutide prescribing criteria, although a full clinical assessment is always required before treatment can be recommended.
Every patient is different, and suitability depends on a range of factors including medical history, current medications and individual treatment goals.
Is the Wegovy Pill Better Than the Injection?
It depends on patients’ preference. Some patients will prefer the convenience of a daily tablet. Others may find a once-weekly injection easier to remember.
The most effective treatment is typically the one that fits comfortably into a person's lifestyle and can be used consistently over time.
The good news is that patients and clinicians now have another option available, allowing treatment to be tailored more closely to individual preferences.
Looking Ahead
The approval of oral Wegovy marks another important milestone in the treatment of obesity and weight-related health conditions.
For years, many people have carried unnecessary shame around their weight. Thankfully, our understanding of obesity continues to evolve. We increasingly recognise that successful weight management is not simply about eating less and moving more. It is about understanding the complex interaction between biology, behaviour, environment and psychology.
The arrival of a tablet formulation will not replace healthy habits, education or ongoing support. However, it may help more people access effective treatment and take the first step towards improving their long-term health.
As healthcare professionals, our role is not simply to prescribe medication. It is to guide, educate and support people through a process that is often far more complex than it appears on the surface.
The Wegovy pill is another tool in that journey, and it will be interesting to see how it shapes the future of weight management in the years ahead.
Interested in starting your weight management journey?
We are offering free in-person assessments to help people start Aster - our online weight management service. You can book an appointment below.
